Gestational trophoblastic disease: classification and prognostic factors (part I)


Cite item

Full Text

Abstract

Major research studies on the current predictors of gestational trophoblastic disease (GTD) were not conducted in Russia. The prognostic value of new prognostic factors such as the level of beta - hCG in spinal fluid in patients with disseminated tumor, the level of placental lactogen (PL) in patients with GTD have not been studied. Until now, there is no earlier criterion of tumor resistance to conventional chemotherapy (parameters beta - HCG, tumor size, etc.). As a result, clinicians often plan GTD treatment of patients according to clinical stage, apply non-standard chemotherapy regimens, which contributes to the development of tumor resistance and significantly worsens the prognosis of the disease. Thus, timely diagnosis and proper staging of GTD, it is important to optimize treatment planning. Proper treatment at an early stage can cure the vast majority of patients, using high-efficiency and low-toxicity standard first line chemotherapy regimens without harm to the reproductive health of women and reduce their quality of life. Comprehensive study of predictors of GTD will allow better planning of treatment, identify early factors tumor resistance to conventional chemotherapy and to develop evidence-based recommendations for optimizing the treatment of patients with GTD.

About the authors

D. A Bistritskaya

N.N. Blokhin Russian Cancer Research Center under the Russian Academy of Medical Sciences

Email: d.cherkashina@gmail.com
аспирант отд-ния онкогинекологии 115478, Moscow, Russian Federation

M. N Tikhonovskaya

N.N. Blokhin Russian Cancer Research Center under the Russian Academy of Medical Sciences

115478, Moscow, Russian Federation

L. A Mescheryakova

N.N. Blokhin Russian Cancer Research Center under the Russian Academy of Medical Sciences

115478, Moscow, Russian Federation

V. V Kuznetsov

N.N. Blokhin Russian Cancer Research Center under the Russian Academy of Medical Sciences

115478, Moscow, Russian Federation

I. Yu Davidova

N.N. Blokhin Russian Cancer Research Center under the Russian Academy of Medical Sciences

115478, Moscow, Russian Federation

References

  1. Redline R.W., Abdul-Karim F. Pathlogy of gestational trophoblastic disease. J. Semin. Oncol. 1995; 22(2): 95-106.
  2. Bracken M.B. Incidence and aetiology of hydatidiform mole: an apidemiologic review. Br. J. Obstetr. Gynaecol. 1987; 94: 1123-35.
  3. Newlands E.S. Clinical management of trophoblastic disease in tfcx^ United Kingdom. Curr. Obstet. Gynecol. 1995; 5(1): 19-24.
  4. Hammond C.B., Borchert L.G., Tyrey L. et al. Treatment of metastatic trophoblastic desiase: Good and poor prognosis. J. Obstetr. Gynaecol. 1973; 115: 451-7.
  5. Kohorn E.I. Single-agent chemotherapy for nonmetaststic gestational trophoblastic neoplasia. Perspectives for the 21st century after three decades of yse. J. Reprod. Med. 1991; 36: 49-55.
  6. Bagshawe K.D. Risk and prognostic factors in trophoblastic neoplasia. Cancer (Philad). 1979; 38: 1373-85.
  7. World Health Organization: Gestation trophoblastic disease. Geneva: WHO; 1983.
  8. Song H.C., Wu P.C., Tong M.Y. et al. Trophoblastic tumors: diagnosis and treatment. Beijing, People's Health, 1981: 128-9.
  9. Soper J.T., Evans A.C., Canaweay M.R. et al. 5-Day methotrexat for women with metastatic gestational-trophoblastic disease. Gyn. One. 1994; 54: 76-9.
  10. Ngan H.Y.S. The praticability of FIGO 2000 staging for gestational trophoblastic neoplasia. Int. J. Gynaecol. Cancer. 2004; 14: 202-5.
  11. Registration Committee for Trophoblastic Disease of the Japan Society of Obstetrics and Gynaecology. Report of the Registration Committee for Trophoblastic Disease. Acta Obstet. Gynaecol. Jpn. 1982.
  12. Bagshawe K.D. Treatment of trophoblastic tumors. Ann. Acad. Med. 1976; 29: 813-20.
  13. Newlands E.S., Bover M., Fisher R.A. Management of placental site trophoblastic tumor. J. Reprod. Med. Obstetr. Gynaecol. 1998; 43(1): 53-9. 14. WHO. World health assembly. Session 53. Resolutions and conclusions. WHO. Geneva, 2000.
  14. Horn L.C., Bilek K. Histologic classification and staging of gestational trophoblastic disease. Gen. Diagn. Pathol. 1997, 143(2-
  15. : 87-101.
  16. Goldstein D.P., Zanten-Przybysz I.V. Revised FIGO staging system for gestational trophoblastic tumors: recommendations regarding therapy. J. Reprod. Med. Obstetr. Gynaecol. 1998; 43(1): 139.
  17. Kohorn E.I. Decision making for chemotherapy administration in patiens with low risk gestational tophoblastic neoplasia. Int. J. Gynaecol. Cancer. 1996; 6: 279-85.
  18. Ngan H.Y. The practicability of FIGO 2000 staging for gestational trophoblastic neoplasia. Int. J. Gynaecol. Cancer. 2004; 14(2): 202-5.
  19. Ng T.Y., Wong L.C. Diagnosis and management of grstational trophoblastic neoplasia. Best Pract. Res. Clin. Obstet. Gynaecol. 2003; 17(6): 893-903.
  20. Szulman A.E., Surti U. The clinicopathologic profile of the partial hydatidiform mole. Obstetr. Gynaecol. 1982; 59: 597-602.
  21. Wolf N.J., Lage J.M. Genetic analysis of gestational trophoblastic disease: a review. Semin. Oncol. 1995; 22(2): 113-20.
  22. Kim S.J. Placental site trophoblastic tumor. Best Pract. Res. Clin. Obstet. Gynaecol. 2003; 17(6): 969-84.
  23. Deng S., Yang X.Y. Diagnosis and therapeutics of placental site trophoblastic tumor. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2002; 24(4): 418-21.
  24. Le-Ming S., Robert J. Kurman. Epithelioid trophoblastic tumor. Am. J. Surg. Pathol. 1998; 23(II): 1393-403.
  25. Shih I.M., Kurman R.J. The pathology of intermediate trophoblastic tumors and tumor-like lesions. Int. J. Gynaecol. Pathol. 2001; 20(1): 31-47.
  26. Ohira S., Yamazaki T., Hatano H., Harada O., Toki T., Konoshi I. Epithelioid trophoblastic tumor metastatic to vagina: an immunohistochemial and ultrastructual study. Int. J. Gynaecol. Pathol. 2000; 19(4): 381-6.
  27. Shih I.M., Kurman R.J. Ki-67 labeling index in the differential diagnisis of exaggerated placental site, placental site trophoblastic tumor, and chorocarcinoma: a double imunohistichemical staining technique using Ki-67 and MelCAM antibodes. Hum. Pathol. 1998; 29(1): 27-47.
  28. Coulson L.E., Kong C.S., Zaloudek C. Epithelioid trophoblastic tumor of the uterus in a postmenopausal woman: a case report and review of the literature. Am. J. Surg. Pathol. 2000; 24(11): 1558-62.
  29. Shimizu T., Yaegashi N. Gestational trophoblastic tumors and resent clinical information [Article in Japanese]. Gan To Kagaku Ryoho. 2002; 29(8): 1363-70.
  30. Kuo K.T., Chen M.J., Lin M.C. Epitelioid trophoblastic tumor of the broad ligament: a case report and review of the literature. Am. J. Surg. Pathol. 2004; 28(3): 405-9.

Copyright (c) 2014 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies